Summary & Overview
HCPCS J0571: Buprenorphine, Oral, 1 mg
HCPCS Level II code J0571 denotes buprenorphine, oral, 1 mg. This medication code is significant nationally because buprenorphine is a core pharmaceutical for opioid use disorder treatment and has growing policy and payer interest due to public health priorities around addiction care. Payers frequently establish coverage criteria, prior authorization rules, and pharmacy benefit management policies that affect access and utilization.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical role and standard service environment, along with what to expect when evaluating payer interactions: common coverage considerations, billing practice notes, and benchmark areas such as utilization and unit pricing. The publication outlines where to look for policy updates, typical billing contexts for oral buprenorphine, and areas where administrative attention is often required.
This national summary is intended for billing managers, pharmacy benefit administrators, clinicians involved in medication-assisted treatment, and policy analysts seeking a clear account of what HCPCS Level II code J0571 represents, which payers commonly manage coverage, and the practical billing and clinical context surrounding this medication. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0571 represents Buprenorphine, oral, 1 mg. This code is used to bill for oral buprenorphine in 1 mg dosage form, a medication commonly employed in the treatment of opioid use disorder and for certain pain management regimens. The service type is medication administration/supply of an oral pharmaceutical, and the typical site of service is outpatient settings such as clinics, office-based practices, and pharmacies where oral medication is dispensed.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 28-year-old adult with opioid use disorder presenting to an outpatient addiction medicine clinic for initiation or continuation of medication-assisted treatment. The clinician prescribes oral buprenorphine, dispensed in 1 mg unit doses (J0571) for either induction, stabilization, or maintenance. Workflow: the patient undergoes assessment including substance use history, physical exam, and review of prior treatments and urine drug screen. If initiating, induction occurs when the patient is in mild-to-moderate withdrawal; small oral doses of buprenorphine are administered and titrated over several hours to control cravings and withdrawal. For stable patients, prescriptions are written for take-home oral tablets or films, with periodic monitoring visits for adherence, counseling referrals, and prescription drug monitoring program checks. Typical site of service is outpatient clinic or specialty addiction treatment center; dispensing may occur at outpatient pharmacies. The patient scenario includes counseling, documentation of consent and treatment plan, and coordination with behavioral health services and payors for medication coverage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no modifier applies |